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combined with interstitial brachytherapy (clinical cases of 
breast cancer recurrence, recurrent melanoma, etc.). 
Contemporary sophisticated CT-based interstitial 
brachytherapy is based on multi-catheter implants piercing 
the tumor or its bed. The same set of elastic tubes can be 
successfully used for hyperthermia treatment. In this 
approach tiny microwave antennas along with thermometers 
(for temperature measurement and adjustments) are inserted 
into the treated volume via brachytherapy applicators. A set 
of CT scans used for treatment planning delivers strict 
geometrical information about 3D orientation of applicators 
within the CTV and enables the physician to plan the best 
pattern of antennas and thermometers to safely heat the 
target volume just before/after irradiation. Such an example 
of reproducible combination of interstitial BT with interstitial 
and superficial HT supported by CT-based treatment planning 
will be presented. 
Joint Symposium: ESTRO-JASTRO: Particle therapy state of 
the art  
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There are mainly four challenges in photon radiotherapy.  
1. Proximity to  critical organs
2. Tumor motion
3. Large tumor volume
4. Radio-resistance
 We have developed and used fiducial markers, four-
dimensional radiotherapy (4DRT) planning concept, and real-
time tumor-tracking radiotherapy (RTRT) system since 1999 
to overcome the first and second problem (Shirato, H. et al. 
Lancet 1999).  It was effective to treat small  tumors such as 
lung, liver, and prostate cancers effectively with the 
accuracy of ± 2 mm even with complex internal organ motion 
(Seppenwoolde, Y. et al. IJROBP 2002).  
We have development a new radiotherapy system with 
Hitachi co ltd  to cure large, moving tumors situated near 
critical organs. It is image-guided spot-scanning proton beam 
therapy system with real-time tumor-tracking system. Cone-
beam CT scan is availabe for precise set-up. Two sets of 
fluoroscope are mounted in the gantry, used for real-time 
tracking of fiducial marker near the tumor, and the proton 
beam is gated to treat large tumors with the accuracy of ± 2 
mm.  The system was approved by Japanese government in 
February 2014 and commercially available as PROBEAT-RT 
(Hitachi, co. ltd., Japan) .  We have been able to successfully 
reduce the size of the system, to make it small enough to be 
installed in the premises of hospitals, by dedicating to the 
spot-scanning Irradiation Technique.  Initial experience of 
this system will be presented.  
Clinical trial has been started since March 2014 for those 
patients who have gain in dose distribution comparing to 
photon therapy.  Acute adverse effects were evaluated and 
shown to be minimal in the initial 6 months. 
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(National Institute of Radiological Sciences) using HIMAC 
(Heavy-Ion Medical Accelerator in Chiba), which was the 
world’s first heavy ion accelerator complex dedicated to 
medical use in a hospital environment. As of February 2014, a 
total of 8,931 patients were treated with carbon ion 
radiotherapy using HIMAC. The results have shown that 
carbon ion radiotherapy has the ability to provide a sufficient 
dose to the tumor without unacceptable morbidity in the 
surrounding normal tissues. Tumors that appear to respond 
favorably to carbon ions include locally advanced tumors and 
those with histologically non-squamous cell type of tumors 
such as adenocarcinoma, adenoid cystic carcinoma, 
malignant melanoma, hepatoma, and bone and soft tissue 
sarcomas. By using biological and physical properties of the 
high-LET carbon ion beams, the efficacy of treatment 
regimen with small fractions in shorter treatment course has 
been also confirmed for almost all type of tumors in our 
carbon ion radiotherapy experience. More than 10,000 
patients treated with carbon therapy worldwide, more than 
80% were treated at NIRS and other facilities in Japan. The 
current facilities and devices may be termed as first-
generation equipment. Making existing equipment smaller 
and less expensive is only the first step. It is be far from 
satisfactory for next-generation facility. One new technique 
that deserves attention as the next generation system is the 
spot scanning beam delivery and the compact 
superconducting magnet mounted rotating gantry. Spot 
scanning beam delivery is designed to treat the complex-
shaped lesions that are difficult targets for the by current 
techniques. Use of the rotating gantry will minimize the time 
for patient positioning and improve patient comfort. Owing 
to simplified treatment set-up procedures and reduced 
treatment time, more patients with poor performance status 
will be eligible for this therapy. We anticipate that the 
introduction of these innovations will not only improve the 
therapeutic outcome but also increase patient throughput. 
The new system will also eliminate the need for making 
compensation filters as well as patient-specific collimators. 
NIRS has finished the construction of the new facility's 
building and the installation of the beam delivery system for 
the pencil beam scanning. A clinical research using the pencil 
beam scanning was in operation with the original fully 
automated patient positioning system since May 2011. We 
could treat a total of almost 1000 patients in the FS year of 
2013 by the broad beam delivery and the pencil beam 
scanning. Good performance of this new carbon pencil beam 
delivery system has been confirmed at NIRS. Regarding the 
compact superconducting magnet mounted rotating gantry, 
the magnets for the gantry were already made and have been 
testing at NIRS successfully. The NIRS novel gantry system 
will be expected to be in operation in early 2016. 
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The ULICE project started in 2009 to address two different 
complementary issues: the development of the appropriate 
instruments for hadrontherapy, with emphasis on carbon ion 
therapy, and the need for intensive collaboration among the 
existing and planned centres, as well as with the European 
hadrontherapy community at large. ULICE was funded by the 
European Commission and involved 20 European institutions 
coordinated by CNAO in Pavia. All the existing and planned 
European ion therapy facilities were involved in the project, 
together with two research centres (CERN and GSI) and 
industrial companies. The approach of ULICE to 
hadrontherapy dealed with all its aspects from medical 
physics to radiobiology, from accelerators to particle beams 
in clinics. The experience being built up in Heidelberg (HIT), 
with more than 2000 patients treated, and Pavia with more 
than 500 patients treated, helped the development of 
hadrontherapy in Europe and provided patients throughout 
Europe access to these centres with treatment according to 
standardized protocols. In addition, other centres planned in 
Europe (MedAustron) which are due to start, ware benefit 
from this experience. One of the most relevant results of the 
ULICE project was the establishment of an international 
board – IONTREB International Ion Beam Therapy Research 
Board - focusing on clinical aspects of the hadrontherapy. 
The project consisted of 3 pillars, Joint Research Activities – 
focused on the development of instruments and protocols, 
Networking – to increase cooperation between facilities and 
research communities, and Transnational access – to allow 
access to hadrontherapy facilities to researchers wanting to 
perform radiobiological and physics experiments as well as 
clinical studies. The Joint Research Activities was 
coordinated by the Medical University of Vienna and focused 
on improving the performance of hadrontherapy facilities 
through the development of various instruments. The JRA 
pillar dealed with clinical issues such as developing novel 
adaptive treatment planning, including clinical protocols that 
combine different types of irradiations, and developing a 
computer assisted patient selection program accessible to 
the whole European community; this was not only enable an 
efficient patient referral to the existing facilities, but also 
allow to pursue the clinical research focused on tumours with 
specific biological characteristics and/or critical location. 
These tools provided a research infrastructure producing 
scientifically sound evidence on the efficacy of 
hadrontherapy. Among the technical issues that ULICE will 
address through JRA is the challenge of reducing the 
dimensions and cost of the gantries. The Networking 
Activities pillar was coordinated by CERN and focuses on 
communication, interaction and interdisciplinary discussion 
among the 20 partners and with the external world, and 
dissemination of the project results to the wider community 
involved in cancer care. Networking activities provided the 
external research community with a clear knowledge of what 
is possible and what is needed in terms of research to be 
carried out at the facilities (both through dissemination 
activities, residential training for researchers and through 
scientific events and publications). The Transnational Access 
was coordinated by the University Hospital of Heidelberg, 
and aims at providing access, at HIT and CNAO, for external 
researchers to the ion therapy facilities for preclinical 
research with the available beams of particles. Beam time 
was allocated to the external researchers through a review 
committee, that assessed the scientific impact of the 
proposed research project. The Transnational Access pillar 
also produced agreed protocols for multi centric clinical 
trials, and allowed external researchers to participate in 
these trials. These goals were facilitated making an extensive 
use of advanced e-science grid technology. 
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Radiation therapy represents an important part of 
multimodal cancer therapy in children. Due to increasing 
efficacy of cancer therapy overall treatment outcomes 
considerably improved. Over the last about 50 years the 
situation in childhood malignancies has changed from an 
inevitably fatal condition to one that is potentially curable, 
with overall 5-year survival rates approaching 80%. However, 
it is well understood that growing tissues are particularly 
sensitive to radiation injury. The burden of multimodal 
treatment consisting often of surgery, cytotoxic and radiation 
therapy jeopardizes the future life of the patients. 
Therefore, reduction of late sequelae and improvement of 
quality of life have become a major concern in paediatric 
cancer survivors.  
Proton beam therapy (PT) has become of increasing interest 
in paediatric oncology. Several dosimetric studies clearly 
demonstrated that PT can better limit the irradiated volume 
as compared to photon technique. Therefore, PT is a 
promising method to reduce the risk for acute and late 
effects, especially with regard to paediatric tumors. Over the 
last decades clinical experience in PT in childhood cancer 
was restricted due to limited availability and very few 
facilities being hospital based. So far, prospective approaches 
were missing, cohorts were small and observation times 
short,  especially  with  regard  to  very  young  children  being  
treated with PT. However, the number of children being 
treated with protons for solid tumors is currently increasing 
due to a growing number of proton facilities being in 
operation worldwide. In Europe and US common indications 
for treatment with PT in the paediatric cohort are as well 
local tumors of central nervous system (CNS) (i.e. glioma, 
medulloblastoma, ependymoma, craniopharyngeoma, and 
intracranial germ cell tumors) as non-CNS tumors (i.e. 
chordoma/chondrosarcoma, and rhabdomyosarcoma). 
Treatment results are promising with regard to local control 
rates. Recent data on neurocognitive functioning and quality 
of life seem to confirm favourable outcome after PT. 
Additional, first experiences suggest that secondary cancer 
induction can be reduced when using PT. Still, more clinical 
data will need to emerge and to quantify the clinical benefit 
of PT. Therefore, PT should be established in a prospective 
approach within multimodality cancer concepts to 
ensure optimal treatment and careful future evaluation. 
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